Abstract
Background/Aim: The evaluation of radiotherapy toxicity in oncologic IBD patients. Defining the optimal patient and treatment factors that would be able to reduce the risk to organs.
Materials and Methods: A review of all published radiotherapy trials was performed to identify the clinical and treatment factors of inflammatory bowel disease’s patients treated for different solid tumors.
Results: Overall, acute (Grade ≥ 3) gastrointestinal complications attributable to RT ranged between 20-21% of the treated patients. A late Grade ≥ 3 gastrointestinal toxicity was developed in a range between 8-29%.
Conclusion: A special attention should be given to the description of IBD location, activity status, concurrent chemotherapy, irradiation dose and technique, in order to minimize post-irradiation morbidity. It is not easy to distinguish late morbidity attributable to radiotherapy due to the IBD itself.
Keywords: Inflammatory bowel diseases, radiotherapy, toxicity.
Reviews on Recent Clinical Trials
Title:Irradiation Toxicity and Inflammatory Bowel Diseases (IBD): Review
Volume: 9 Issue: 1
Author(s): Tolia Maria, Zygogianni Anna, Kouvaris John R., Tsoukalas Nikolaos, Kokakis Ioannis, Kyrgias George, Mystakidou Kyriaki and Kouloulias Vasileios
Affiliation:
Keywords: Inflammatory bowel diseases, radiotherapy, toxicity.
Abstract: Background/Aim: The evaluation of radiotherapy toxicity in oncologic IBD patients. Defining the optimal patient and treatment factors that would be able to reduce the risk to organs.
Materials and Methods: A review of all published radiotherapy trials was performed to identify the clinical and treatment factors of inflammatory bowel disease’s patients treated for different solid tumors.
Results: Overall, acute (Grade ≥ 3) gastrointestinal complications attributable to RT ranged between 20-21% of the treated patients. A late Grade ≥ 3 gastrointestinal toxicity was developed in a range between 8-29%.
Conclusion: A special attention should be given to the description of IBD location, activity status, concurrent chemotherapy, irradiation dose and technique, in order to minimize post-irradiation morbidity. It is not easy to distinguish late morbidity attributable to radiotherapy due to the IBD itself.
Export Options
About this article
Cite this article as:
Maria Tolia, Anna Zygogianni, R. John Kouvaris, Nikolaos Tsoukalas, Ioannis Kokakis, George Kyrgias, Kyriaki Mystakidou and Vasileios Kouloulias, Irradiation Toxicity and Inflammatory Bowel Diseases (IBD): Review, Reviews on Recent Clinical Trials 2014; 9 (1) . https://dx.doi.org/10.2174/1574887109666140423123845
DOI https://dx.doi.org/10.2174/1574887109666140423123845 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nitric Oxide and Dietary Factors: Part V Summary/Conclusion and References
Vascular Disease Prevention (Discontinued) Pro-Inflammatory Gene Variants in Myocardial Infarction and Longevity: Implications for Pharmacogenomics
Current Pharmaceutical Design Adenosine Receptors: What We Know and What We are Learning
Current Topics in Medicinal Chemistry Vascular Effects of Estrogenic Menopausal Hormone Therapy
Reviews on Recent Clinical Trials Immunopathology of Type 1 Diabetes and Immunomodulatory Effects of Stem Cells: A Narrative Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia
Current Medicinal Chemistry Drug Transport Across the Blood-Brain Barrier and the Impact of Breast Cancer Resistance Protein (ABCG2)
Current Topics in Medicinal Chemistry Treatment of Central Nervous System Tuberculosis Infections and Neurological Complications of Tuberculosis Treatment
Current Pharmaceutical Design Nimodipine Reappraised: An Old Drug With a Future
Current Neuropharmacology Cardiovascular Effects of Modulators of Soluble Guanylyl Cyclase Activity
Cardiovascular & Hematological Agents in Medicinal Chemistry Fibroblast Growth Factor 2: From Laboratory Evidence to Clinical Application
Current Vascular Pharmacology Anti-Inflammatory and Anti-Neoplastic Actions of Resveratrol
Current Nutrition & Food Science Platelet-neutrophil Interactions as a Target for Prevention and Treatment of Transfusion- related Acute Lung Injury
Current Pharmaceutical Design Free Radicals and Antioxidants: How to Reestablish Redox Homeostasis in Chronic Diseases?
Current Medicinal Chemistry Role of Endothelial Progenitor Cell Mobilization After Percutaneous Angioplasty Procedure
Current Pharmaceutical Design The Pathology Induced by Highly Active Antiretroviral Therapy Against Human Immunodeficiency Virus: an Update
Current Medicinal Chemistry Angiogenesis as Risk Factor for Plaque Vulnerability
Current Pharmaceutical Design Dermatologic Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Clinical Evidence and Therapeutic Treatments at the Time of the Coronaviruses Responsible for SARS: A Perspective and Points of view with a Focus on Vascular Endothelium
Coronaviruses Novel and Emerging Drugs for Systemic Lupus Erythematosus: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry